68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of the extent of the disease in patients with malignant endocrine tumors: our experience (preliminary results) Abstract #115

Introduction: In neuroendocrine tumors (NETs), the workup is often difficult not only to visualize but also to co-localize the lesions anatomically. Liver and bones are one of the most frequent sites of metastases in patients with endocrine tumors. The Tyr3-octreotate (TATE) somatostatin analogue differs from TOC in that the terminal threonine replaces threoninol. The terminal threonine results in a higher receptor binding (mainly subtype 2) and better internalisation, with the consequence that tumor uptake of the tracer is intense.
Aim(s): To evaluate the diagnostic value of 68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of disease extent in patients with malignant neuroendocrine tumors in our institution.
Materials and methods: 68Ga-DOTA-TATE PET-CT and 99mTc-HYNIC-TOC SPECT/CT studies were performed in nine patients. The interval time between of these two studies was 2 – 28 weeks. Conventional scintigraphy was acquired on the hybrid gamma camera SPECT/CT in 2-4 h after intravenous injection of 99mTc-HYNIC-TOC. The injected activity was 550-740 MBq (15-20mCi). The following views were gathered: planar AP, PA and SPECT/CT of the chest and abdomen. PET-CT scans were acquired 45 – 60 min postinjection of 120 – 200 MBq (3.5 – 5.5 mCi) of 68Ga-DOTA-TATE. Data acquisition was performed with a 15-cm axial field of view (FOV) and 55-cm transaxial FOV PET-CT scanner. Patients were imaged in 3-dimensional mode with the duration of acquisition 3 - 5 min per bed position in emission mode.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Norbert Szalus

To read results and conclusion, please login ...

Further abstracts you may be interested in

#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#777 Laparoscopic Surgery of Functioning Neuroendocrine Tumors of Pancreas
Introduction: Laparoscopic surgery is a feasible technique for benign pancreatic pathologies and has been increasingly reported for neuroendocrine tumors of the pancreas.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Viktor Shkarban
#1087 Gastro-Entero-Pancreatic Mixed Adenoneuroendocrine Tumors. Report of Four Cases.
Introduction: Mixed adenoneuroendocrine carcinomas (MANECs) is an uncommon entity with ill-defined clinicopathologic characteristics.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Georgia Karayannopoulou
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.